Cardiovascular disease (CVD) development is closely related to lifestyle characteristics and associated risk factors.
There is an overwhelming scientific evidence that lifestyle modifications and reduction of risk factors can slow the development of CVD both before and after the occurrence of a CV event.
Primary CVD prevention is aimed at the healthy population, individuals who have several CV risk factors or 1 CV risk factor at a very high level, and individuals whose risk for a CV event is high. Secondary CVD prevention is aimed at individuals with confirmed CVD.
The prescription omega-3 fatty acid icosapent ethyl significantly reduces the need for revascularization in patients with elevated triglycerides who were already on statins and were at increased cardiovascular (CV) risk, reveals the latest data from the REDUCE-IT REVASC analysis presented during the SCAI* 2020 Meeting.
Having sufficient and healthy sleep, in addition to adopting healthy lifestyle based on the AHA* Life’s Simple 7 (LS7) guidelines, can reduce the risk of cardiovascular diseases (CVD), according to the longitudinal MESA** Sleep Study presented at EPI Lifestyle 2020 Scientific Sessions.
Sleeping less than 6 hours per night and having poor quality sleep were independently associated with a greater risk of subclinical atherosclerosis, including sites beyond the heart, according to the PESA* study.
Using aspirin for primary prevention of cardiovascular (CV) disease was associated with a reduced risk of CV events but an increased risk of major bleeding, a new meta-analysis of 13 large randomized trials shows.
A healthy lifestyle during the menopausal transition, as typified by abstinence from smoking, regular exercise, and a healthy diet, is associated with less development of subclinical atherosclerosis, according to data from the prospective SWAN* cohort.
Increasing cardiorespiratory fitness (CRF) is associated with decreasing risk of coronary heart disease (CHD), even in an apparently healthy, low-risk population with no prior history of cardiovascular (CV) disease (CVD), according to the HUNT*3 Study.
Women diagnosed with nonmetastatic breast cancer who were adherent to cardiovascular disease (CVD) medications pre-diagnosis had a high risk of becoming nonadherent post-cancer treatment, with nonadherence increasing their risk of CV events, according to a poster presented at the recent San Antonio Breast Cancer Symposium (SABCS 2018).
Gaining weight after quitting smoking may temporarily increase a person’s risk of type 2 diabetes (T2D), a recent US study found, with the risk increasing proportionally with the amount of weight gained. However, quitting smoking is still tied to a reduced risk of death due to cardiovascular disease (CVD).
Targeting a low-density lipoprotein cholesterol level <70 mg/dL following an ischaemic stroke of atherosclerotic origin helps to avoid one in four subsequent major vascular events without increasing the risk of intracranial haemorrhage over about 5 years of follow-up, according to data from the Treat Stroke to Target trial.
Early initiation of rhythm-control therapy led to a significantly reduced risk of major adverse cardiovascular (CV) outcomes compared with usual care (typically rate control) in patients with newly diagnosed atrial fibrillation (AF) at risk of stroke, reveals the EAST-AFNET 4* trial presented at ESC 2020.